Brief: Oragenics Inc Files For Mixed Shelf Of Up To $40 Million
Brief: Oragenics Discloses One-For-Sixty Reverse Stock Split
Oragenics gains on toxicology data for COVID vaccine candidate study
Brief: Oragenics Reports Favorable Toxicology Results For Its COVID-19 Intranasal Vaccine Candidate
Brief: Oragenics Inc Receives NYSE American Notice
Brief: Oragenics Announces New Chair
Brief: Oragenics Inc Says Effective Dec 15, Kimberly Murphy, Co's President, CEO, Was Appointed Co's Interim Chief Financial Officer, Secretary, Treasurer
Brief: Oragenics Inc Says On Nov 16, Michael Sullivan, CFO Notified Co That He Would Be Resigning, Effective Dec 14
Brief: Oragenics Inc Confident In Strategic Direction And Specifically in Plans To Advance N-COV2-1
Brief: Oragenics Reports Preliminary Data For Intranasal COVID-19 Vaccine Candidate
Oragenics names new CEO, shares rise
Brief: Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy As President And Chief Executive Officer
Brief: Oragenics Announces Publication Of Positive Data For Its Nt-Cov2-1 Intranasal Covid-19 Vaccine Candidate In Scientific Reports
Brief: Oragenics Extends Collaboration To Develop Vaccines Against Future Variants Of Coronaviruses
Brief: Oragenics Inc Receives Audit Opinion With Going Concern Explanation
U.S. STOCKS ON THE MOVE-JX Luxventure, Statera Biopharma, Pfizer
Oragenics up on starting COVID-19 vaccine candidate study in rabbits
Brief: Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate
Brief: Oragenics Engages KBI Biopharma To Support Development Of Intranasal Covid-19 Vaccine Candidate Nt-Cov2-1